Clinical Trials Logo

Filter by:
NCT ID: NCT01762527 Completed - Clinical trials for Adverse Effects for Adaptive RT of Bladder Cancer

Adaptive Radiotherapy Using Plan Selection for Bladder Cancer

plan selection
Start date: October 2012
Phase: N/A
Study type: Interventional

This protocol describes a Phase 2 clinical trial of online adaptive Radiotherapy, using a library of 3 dose plans corresponding to Small, Medium and Large size bladder. The procedure includes 'Common Toxicity Criteria for Adverse Effects'(CTCAE) for registration of adverse effects (baseline, every 2'nd week during RT, 2 weeks, 3, 6, 12 and 24 month after RT) as well as cineMR for intra-fractional motion (baseline and every week during RT). Patients receive standard non-adaptive RT in the first week. Delineations of the bladder on the Cone-Beam scans (CBCT) from first week of treatment are used for planning the Small and Medium size bladder plans. Large size plan are the standard non-adaptive treatment plan used for the first week of treatment. A margin of 5 mm for intra fractional movement is used.

NCT ID: NCT01762241 Completed - Prostate Cancer Clinical Trials

Xbox Kinect Training in Men With Prostate Cancer

Start date: February 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the effect of 12 weeks systematically training using the Xbox Kinect system. Outcome measures are made on physical function, quality of life, fatigue and metabolic parameters.

NCT ID: NCT01761721 Completed - Endometrial Cancer Clinical Trials

Robot-assisted Laparoscopic Hysterectomy-RALH- Postoperative Complications, Quality of Life and Health Economics

RALH
Start date: January 2013
Phase: N/A
Study type: Observational [Patient Registry]

The propose of this study is to describe recovery and experience of pain and health related quality of life after robot-assisted laparoscopic hysterectomy for women with Endometrial Cancer or Atypical Complex Hyperplasia.

NCT ID: NCT01760668 Completed - Turner Syndrome Clinical Trials

Aortopathy in Persons With Bicuspid Aortic Valve, Turner and Marfan Syndrome

Start date: February 2013
Phase: N/A
Study type: Observational

The study aim is: 1. To examine aortic tissue by light microscopy 2. To examine aortic tissue by electron microscopy 3. To study changes in the epigenome and transcriptome of the X chromosome specific to aortic tissue. 4. To examine aortic tissue using biochemistry including proteomics. 5. To establish the karyotype of fibroblasts with standard chromosome examination on 10 meta-phases as well as by fluorescent in situ hybridization (FISH) with probes covering the X and Y chromosome. Using the latter 200 meta-phases will be examined. 30 controls who did not die from aortic dissection or dilation will be recruited from The Department of Forensic Medicine at Aarhus University Hospital. The investigators will subject samples of aortic tissue from women undergoing prophylactic aortic surgery due to either Marfan syndrome or bicuspid aortic valve to the same panel of examinations (except karyotyping). Lastly the investigators will compare the results from the three groups (Turner syndrome, Marfan syndrome and Bicuspid aortic valve).

NCT ID: NCT01760369 Completed - Clinical trials for Regional Cerebral Oxygen Saturation During Head Rotation

Study of the: Effect of Head Rotation in Prone Position on Regional Cerebral Oxygen Saturation.

NIRS
Start date: October 2012
Phase: N/A
Study type: Observational

The purpose of this study is to determine whether head rotation in prone positon affects regional cerebral oxygenation (rSO2)in anesthetized patients undergoing lower back surgery.

NCT ID: NCT01758380 Completed - Clinical trials for Type 2 Diabetes Mellitus

Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan

STEADFAST
Start date: January 2013
Phase: Phase 4
Study type: Interventional

To evaluate vildagliptin as compared to gliclazide, given in combination with metformin in Muslim patients with type 2 diabetes fasting during Ramadan.

NCT ID: NCT01757678 Completed - Clinical trials for Coronary Artery Disease

HeartFlowNXT - HeartFlow Analysis of Coronary Blood Flow Using Coronary CT Angiography

HFNXT
Start date: September 2012
Phase: N/A
Study type: Interventional

To determine the diagnostic performance of FFRCT by coronary computed tomographic angiography (cCTA), as compared to cCTA alone, for non-invasive determination of the presence of a hemodynamically significant coronary lesion, using direct measurement of fractional flow reserve (FFR) during cardiac catheterization as a reference standard.

NCT ID: NCT01756313 Completed - Clinical trials for Photodynamic Therapy

Optimizing Uptake of Methylaminolevulinat With Fractional Ablative Laser Technique

Start date: May 2012
Phase: Phase 4
Study type: Interventional

The objectives of this study is to investigate if pre-treating the skin with an ablative fractional laser that creates small micropores in the skin: 1. Increases the uptake of Methylaminolevulinat (MAL) in the skin. 2. Decreases the required incubation time of MAL when performing photo dynamic therapy.

NCT ID: NCT01756300 Completed - Hypertension, Renal Clinical Trials

RENABLATE Feasibility Study CS156 (EC12-02) Study of Catheter Based Renal Denervation to Treat Resistant Hypertension

Start date: December 2012
Phase: Phase 1
Study type: Interventional

The RENABLATE feasibility study is a prospective, multi-center, non-randomized feasibility study to evaluate the safety and effectiveness of the investigational multi-electrode ablation catheter and integrated ablation system to treat resistant hypertension.

NCT ID: NCT01754935 Completed - Clinical trials for Rheumatoid Arthritis

A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

Start date: January 2013
Phase: Phase 2
Study type: Interventional

The current study is designed to evaluate the safety and efficacy, including MRI imaging, across a range of VX-509 doses in subjects with active rheumatoid arthritis (RA) who have had an inadequate response to disease-modifying antirheumatic drugs (DMARDs).